Ferroquine

Sanofi

Product vision
  • Uncomplicated malaria treatment for single-exposure radical cure (SERC) and/or resistance management

MoA
  • Ferroquine (FQ), belonging to 4-aminoquinolines: inhibition of haem detoxification
Key features
  • Long duration of plasma exposure
Status
  • Two phase II studies in combination with OZ439 were completed in 2020
Next milestone
  • Conduct a phase I combination safety study, before a phase IIb study of FQ with a new partner drug
Previously
  • Ferroquine discovered by CNRS Lille and transferred to Sanofi; rights transferred from Sanofi to MMV
MMV Project Director
  • Dr Florian Wartha